title: Rapid regression of Kaposi's sarcoma of the hard palate under therapy with boosted elvitegravir-containing fixdose antiretroviral combination therapy.
abstract: BACKGROUND
  Kaposi's sarcoma (KS) is a rare vascular tumor that may occur in a severe, rapidly progressive form, namely in HIV/AIDS patients. HIV-associated KS mainly affects the skin and mucous membranes.
  
  
  METHODS
  We report about an HIV-positive patient who presented with an exophytic growing tumor in the region of the hard palate and severe problems regarding his dental status. Histological examination revealed evidence of AIDS-related KS. Antiretroviral therapy initiation with elvitegravir/cobicistat/emtricitabine(FTC)/tenofovirdisoproxilfumarat (E/c/F/T-fix dose combination) resulted in rapid complete remission of the KS within 2 months.
  
  
  CONCLUSIONS
  In this case of a treatment-naive HIV-infected patient with coexisting KS, antiretroviral therapy with E/c/FTC/TDF was very well suited to achieve rapid complete remission of KS.
authors.affiliation: Department for Internal Medicine II/Infectious Diseases, Goethe-University Hospital, Frankfurt am Main, Germany. dcgundolf@yahoo.de.
authors.forename: Gundolf
authors.initials: G
authors.lastname: Schüttfort
authors.affiliation: Department for Internal Medicine II/Infectious Diseases, Goethe-University Hospital, Frankfurt am Main, Germany.
authors.forename: Timo
authors.initials: T
authors.lastname: Wolf
authors.affiliation: Department for Internal Medicine II/Infectious Diseases, Goethe-University Hospital, Frankfurt am Main, Germany.
authors.forename: Phillip
authors.initials: P
authors.lastname: de Leuw
authors.affiliation: Department for Internal Medicine II/Infectious Diseases, Goethe-University Hospital, Frankfurt am Main, Germany.
authors.forename: Gerrit
authors.initials: G
authors.lastname: Kann
authors.affiliation: Department for Orofacial Surgery, Goethe-University Hospital, Frankfurt am Main, Germany.
authors.forename: Maximilian
authors.initials: M
authors.lastname: Blume
authors.affiliation: Department for Internal Medicine II/Infectious Diseases, Goethe-University Hospital, Frankfurt am Main, Germany.
authors.forename: Hans-Reinhard
authors.initials: HR
authors.lastname: Brodt
authors.affiliation: Department for Internal Medicine II/Infectious Diseases, Goethe-University Hospital, Frankfurt am Main, Germany.
authors.forename: Christoph
authors.initials: C
authors.lastname: Stephan
mesh_terms: D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D023241:Antiretroviral Therapy, Highly Active / Q000379:methods*; D015658:HIV Infections / Q000150:complications / Q000188:drug therapy*; D006801:Humans; D008297:Male; D010157:Palatal Neoplasms / Q000473:pathology*; D021362:Palate, Hard / Q000473:pathology*; D015363:Quinolones / Q000627:therapeutic use*; D012514:Sarcoma, Kaposi / Q000473:pathology*; D016896:Treatment Outcome
chemical_list: D019380:Anti-HIV Agents; D015363:Quinolones; C509700:elvitegravir
keywords: Elvitegravir; HIV; Kaposi